Literature DB >> 12671335

Common questions and answers in the management of hypertension: Am I more likely to develop diabetes if I have high blood pressure?

Raymond R Townsend1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12671335      PMCID： PMC8099337          DOI： 10.1111/j.1524-6175.2003.01926.x

Source DB:  PubMed          Journal:  J Clin Hypertens (Greenwich)        ISSN： 1524-6175            Impact factor:   3.738


× No keyword cloud information.
  8 in total

1.  Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial.

Authors:  L Hansson; L H Lindholm; L Niskanen; J Lanke; T Hedner; A Niklason; K Luomanmäki; B Dahlöf; U de Faire; C Mörlin; B E Karlberg; P O Wester; J E Björck
Journal:  Lancet       Date:  1999-02-20       Impact factor: 79.321

2.  Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients.

Authors:  S Yusuf; P Sleight; J Pogue; J Bosch; R Davies; G Dagenais
Journal:  N Engl J Med       Date:  2000-01-20       Impact factor: 91.245

3.  Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).

Authors: 
Journal:  JAMA       Date:  2002-12-18       Impact factor: 56.272

4.  Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus. Atherosclerosis Risk in Communities Study.

Authors:  T W Gress; F J Nieto; E Shahar; M R Wofford; F L Brancati
Journal:  N Engl J Med       Date:  2000-03-30       Impact factor: 91.245

5.  High normal blood pressure, hypertension, and the risk of type 2 diabetes in Japanese men. The Osaka Health Survey.

Authors:  T Hayashi; K Tsumura; C Suematsu; G Endo; S Fujii; K Okada
Journal:  Diabetes Care       Date:  1999-10       Impact factor: 19.112

6.  Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol.

Authors:  Björn Dahlöf; Richard B Devereux; Sverre E Kjeldsen; Stevo Julius; Gareth Beevers; Ulf de Faire; Frej Fyhrquist; Hans Ibsen; Krister Kristiansson; Ole Lederballe-Pedersen; Lars H Lindholm; Markku S Nieminen; Per Omvik; Suzanne Oparil; Hans Wedel
Journal:  Lancet       Date:  2002-03-23       Impact factor: 79.321

7.  Incidence of diabetes and gout in hypertensive patients during 8 years of follow-up. The General Practice Hypertension Study Group.

Authors:  T Grodzicki; A Palmer; C J Bulpitt
Journal:  J Hum Hypertens       Date:  1997-09       Impact factor: 3.012

8.  Insulin resistance in essential hypertension.

Authors:  E Ferrannini; G Buzzigoli; R Bonadonna; M A Giorico; M Oleggini; L Graziadei; R Pedrinelli; L Brandi; S Bevilacqua
Journal:  N Engl J Med       Date:  1987-08-06       Impact factor: 91.245
  8 in total
  1 in total

1.  Volumetric analysis of central body fat accurately predicts incidence of diabetes and hypertension in adults.

Authors:  Jacob T Gibby; Dennis K Njeru; Steven T Cvetko; Ray M Merrill; Benjamin T Bikman; Wendell A Gibby
Journal:  BMC Obes       Date:  2015-02-25
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.